Objective: This study examined the reciprocal associations between sleep macrostructure and levels of cellular inflammation in rheumatoid arthritis (RA) patients and controls. Methods: RA patients (n = 24) and matched controls (n = 48) underwent all-night polysomnography, along with assessment of spontaneous-and Toll-like receptor-4-stimulated monocytic production of tumor necrosis factor α (TNF) and interleukin (IL)-6 at 11:00 PM and 8:00 AM. Higher levels of stimulated production of TNF at 11:00 PM were associated with higher sleep efficiency (0.74). In turn, sleep efficiency had a countervailing relationship on TNF production at 8:00 AM (À0.64). Higher levels of spontaneous and stimulated production of IL6 at 11:00 PM were associated with more stage 3 (0.39), stage 4 (0.43), and slow-wave sleep (0.49), with evidence that stage 4 had a countervailing relationship on IL6 production at 8:00 AM (À0.60). Conclusions: RA patients show evidence of sleep fragmentation, greater sleep depth, and higher levels of cellular inflammation. Sleep maintenance and sleep depth show countervailing relationships with evening and morning levels of monocytic production of TNF and IL-6, respectively, which support the hypothesis of a feedback loop between sleep maintenance, slow-wave sleep, and cellular inflammation that is cytokine specific.
INTRODUCTION
I mpaired sleep quality and related daytime dysfunction are consistently reported in rheumatoid arthritis (RA) populations. Clinically significant sleep disturbance is found in more than 60% of RA patients (1, 2) , which is thought to have an adverse impact on systemic inflammation, synovitis, joint function, and quality of life, as well as medical comorbidity and all-cause mortality (3) (4) (5) (6) (7) (8) . Despite the prevalence of sleep problems in RA, few studies have objectively examined sleep using polysomnography (PSG), and this previous work is limited by small sample size (9-13), lack of control group (12, 13) , and inadequate consideration of confounding factors (14) . PSG provides a laboratory-based assessment of disturbances of sleep continuity and sleep architecture. Sleep continuity includes total sleep time, sleep latency, sleep efficiency, and wake after sleep onset. Sleep architecture is characterized by nonrapid eye movement (NREM) sleep including amounts of stages 1 and 2 sleep and stages 3 and 4 sleep (slow-wave sleep [SWS] ); SWS or deep sleep is thought to be important in the restorative function of sleep as compared with stages 1 and 2 sleep. Rapid-eye-movement (REM) sleep includes measures of REM sleep amount, REM latency, REM density, and REM duration.
Animal models, cell culture data, and the use of antiinflammatory cytokine antagonist treatments provide converging evidence that dysregulation of the proinflammatory cytokine network underlies synovial inflammation in patients with RA (15) . Proinflammatory cytokines play a key role in the progression of RA (15) . Moreover, proinflammatory cytokines show potent additive effects; tumor necrosis factor-α (TNF) strongly induces production of interleukin (IL)-1β and IL-6, whereas TNF blockade potently antagonizes IL-6 and TNF production.
In RA patients who show increases in levels of proinflammatory cytokine activity, sleep deprivation induces an exaggerated increase in self-reported pain as compared with responses in controls (16) . Sleep disturbance is also associated with increases in circulating levels of IL-6 and TNF, but not IL-1, and increases in transcriptional expression of IL-6 and TNF (17, 18) . To test the causal role of sleep in regulating inflammation, sleep deprivation has been found to induce increases in the spontaneous or constitutive monocytic expression of IL-6 and TNF. Monocytes make up approximately 5% of circulating leukocytes and are a major contributor to proinflammatory cytokine production in peripheral blood. In addition, sleep loss induces increases in lipopolysaccharide (LPS)-stimulated monocytic production of IL-6 and TNF (3, (17) (18) (19) . LPS acts by stimulating the Toll-like receptor (TLR)-4. In turn, increases in TLR-4-stimulated production of IL-6 and TNF correlate with symptoms of fatigue (20, 21) ; elevated TNF levels also occur in association with fatigue and daytime sleepiness in patients with chronic fatigue syndrome, insomnia, or obstructive sleep apnea (22) .
Alternatively, animal models suggest that inflammation can have reciprocal effects on sleep (23) , with evidence that cytokines have both somnogenic and inhibitory effects on sleep depending on the cytokine, plasma level, and circadian phase (24) . For example, TNF and IL-1β influence regulation of sleep macrostructure, under both physiological and pathological conditions, in which central or systemic injections of TNF induce dose-dependent increases of duration and intensity of NREM sleep; however, when dosage of cytokine is increased, both NREM and REM sleep are inhibited (22) . Opposite effects on NREM sleep are exerted by inhibitors of these cytokines (22) . Finally, central administration of IL-6 modulates NREM sleep and induces sleep fragmentation in rats (25) . In humans, we have found that a TNF receptor antagonist, which decreases bioactivity of TNF as well as IL-6, decreases amounts of REM sleep (26) .
Less is known about the reciprocal relationship between inflammation and sleep in humans, with no available data in RA patients. On the basis of previous findings from animal and human experimental studies, we hypothesized that sleep fragmentation would be associated with increases in monocytic expression of TNF and IL-6 in the morning. In contrast, given the somnogenic effects of proinflammatory cytokines, we further hypothesized that a countervailing relationship between evening levels of cellular inflammation and sleep continuity, in which increases in monocytic expression of TNF and IL-6 in the evening would be associated with sleep maintenance, as opposed to sleep fragmentation. Furthermore, given compelling animal data that proinflammatory cytokines induce NREM or slowwave sleep, we hypothesized that increases in monocytic expression of proinflammatory cytokines in the evening would be associated with increases in slow-wave sleep. Moreover, because SWS is thought to have a restorative effect on the immune system, increases in slow wave would then have countervailing effects on cellular inflammation and be associated with decreases in morning expression of proinflammatory cytokines. Finally, we hypothesized that RA patients will show increases in cellular inflammation, greater amounts of NREM sleep, and specifically greater amounts of stages 3 and 4 sleep or SWS as compared with controls. Hence, the overarching objectives of this study were (1) to determine the nature and severity of disordered sleep using PSG in RA patients versus controls and (2) to examine the reciprocal associations between sleep macrostructure and evening and morning levels of constitutive or spontaneous inflammation and of stimulated monocytic production of proinflammatory cytokines. Levels of cellular inflammation were obtained before and after the nocturnal sleep period to evaluate the direction of the reciprocal relationship between inflammation, sleep continuity, and slow-wave sleep. The cellular sources of proinflammatory cytokine activity, as opposed to circulating levels of proinflammatory cytokines, were assessed by measuring the production of proinflammatory cytokines by monocytes after ligation of the TLR-4 with LPS in monocytes. In addition to assay of TLR-4-stimulated production of IL-6 and TNF, we evaluated the resting or constitutive expression of proinflammatory cytokines by monocytes (i.e., spontaneous monocytic production of IL-6 and TNF).
MATERIALS AND METHODS

Design Overview
The current study was part of an experimental study that evaluated the effects of partial night sleep deprivation on pain symptoms in RA patients (16) . In this report, only PSG data from the baseline night, before sleep deprivation, were used for cross-sectional comparison of RA patients (n = 24) as well as age-, sex-, and body mass index (BMI)-matched comparison controls (n = 48). Data were collected between November 2006 and July 2015. Study procedures were approved by the University of California, Los Angeles, Institutional Review Board, and all participants provided informed consent.
Participants
Details about recruitment, eligibility screening, and characteristics of participants have previously been described (16) . For both RA patients and controls, the following exclusion criteria were applied as ascertained by medical history and physical examination: active, uncontrolled medical disorders; chronic infections; comorbid pain disorders; current psychiatric disorders; steroid use exceeding 10 mg of prednisone per day; multiple daily doses of opioids; use of psychotropic or hypnotic medications; substance use; BMI of greater than 35 kg/m 2 ; and pregnancy. Screening laboratory tests (complete blood count and metabolic panel) confirmed reference range results for all participants. Briefly, RA patients fulfilled the 1987 American College of Rheumatology revised criteria for RA according to diagnostic evaluation performed by a study rheumatologist and had a stable disease course without flares/were stable on a disease-modifying antirheumatic drug (DMARD) regimen 3 months or greater before study entry. The RA patients reported taking the following medications: DMARDs (71%), TNF inhibitors (42%), nonsteroidal anti-inflammatory drugs (NSAIDs, 54%), steroids (13%), beta blockers (8%), other antihypertensive medications (29%), statins (13%), and levothyroxine (13%). Only one RA patient reported use of an opioid (not regular intake), one patient was taking an antidepressant (bupropion), and one patient was prescribed hormonal replacement therapy. Overall, a low number of comparison controls were taking any type of medication. None of the controls were taking NSAIDs, steroids, opioids, or beta blockers; statins (14%) were the most commonly prescribed medication.
Regular bedtimes and rising times (between 10:30 PM and 07:30 AM) were confirmed for all participants via administration of 2-week sleep diaries before the PSG assessment. For both groups, primary sleep disorders were ruled out through a comprehensive medical history in conjunction with PSG screening as described later. Diagnoses of psychopathologies and/or insomnia disorder were determined through Structured Clinical Interview for DSM-IV.
Procedures
Sleep Assessment
Before assessment of sleep, participants underwent a night of adaptation to acclimate participants to the PSG protocol and to exclude those with primary sleep disorders such as sleep apnea (apnea-hypopnea index > 15) or nocturnal myoclonus (periodic limb movements during sleep index > 10). PSG data obtained during the night after adaptation were used for analyses. Details about the sleep protocol and electroencephalogram (EEG) sleep methods have previously been described (27) . A standard PSG montage was used, including six EEG channels (C 4 , F 4 , O 2 referenced to M 1 ; C 3 , F 3 , O 1 referenced to M 2 ), bilateral electro-oculogram, bipolar electromyogram, pulse oximetry, abdominal respiratory effort, and ECG. Data from each 30-second epoch were entered into a computer program that tallied the summary statistics for each person. All sleep records were visually scored in accordance with Rechtschaffen and Kales criteria (28) using methods detailed (27, 29) . Sleep onset was defined as the first minute of stage 2 or REM sleep, followed by at least 8 minutes of sleep in the next 9 minutes. A REM period was defined by not less than 3 consecutive minutes of REM sleep. Sleep efficiency was the ratio of total sleep time to the time in bed, multiplied by 100. Sleep architecture was defined as the duration of time spent asleep in NREM sleep (stages 1-4). REM density was an estimate of the number of eye movements per minute of REM sleep, scored on a scale of 0 to 4 per 30-second epoch but expressed on a scale of 0 to 8 per minute. Certified sleep research technicians were regularly tested on scoring reliability, and high standards were maintained: sleep latency (r = .96), REM latency (r = .99), REM density (r = .91), amounts of stages 3 and 4 (r = .85), and total sleep time (r = .99).
During the study days, both groups followed identical rest/activity schedules: no strenuous activity; lights out at 11:00 PM, uninterrupted sleep, good morning time at 07:00 AM. Caffeine was not allowed after 13:00 PM, and no eating or drinking (except for water and medications) was allowed after 8:00 PM. Before entry into the sleep protocol, participants underwent urine toxicology to rule out current substance use.
Questionnaires
To assess subjective measures of sleep, pain, and health-related function, the following validated questionnaires were administered: Pittsburgh Sleep 
RA Disease Activity
For all RA patients, a structured clinical comprehensive joint count assessment was completed; disease activity score (DAS) 28 − C-reactive protein (CRP)/erythrocyte sedimentation rate (ESR) were calculated (31).
Systemic Inflammation and Cellular Production of Proinflammatory Cytokines
CRP was measured using high-sensitivity immunoassay on a BN-II System (Dade-Behring, Newark, Del). Samples were automatically diluted 1:20 with N Diluent. This technique has a limit of detection of 0.175 mg/l and intra-and interassay coefficients of variation of less than 4%, and all samples had detectable levels of CRP. ESR was estimated by a modified Westergren method (Seditainer; Becton Dickinson, Oxford, Unite Kingdom).
Monocyte intracellular production of TNF and IL-6 at rest (i.e., spontaneous) and in response to lipopolysaccharide (LPS) (i.e., TLR-4) stimulation of whole-blood leukocytes was assessed by flow cytometry (as described previously (32)); measures were obtained at 11:00 PM (before lights out) and at 8:00 AM in the following morning. Briefly, heparintreated blood was mixed without (spontaneous) and with 100 pg/ml LPS (Sigma, St Louis, Mo) and 10 μg/mL brefeldin A (Sigma) and incubated for 4 hours at 37°C. After cells were permeabilized in fluorescenceactivated cell sorting permeabilizing buffer (BD Biosciences, San Jose, Calif ) and fluorescence-conjugated antibodies were added, approximately 12,000 CD14 events were counted to determine the net unstimulated or spontaneous and stimulated percentage of cytokine-secreting monocytes, with quadrant coordinates set based on unstimulated cells. Intra-and interassay coefficient of variation is less than 7%.
Statistics
Before analyses, all data were explored; normality was determined graphically by inspection of Q-Q plots and histograms and numerically through the Kolmogorov-Smirnov test. Measures observed to be skewed were natural log transformed. Comparisons of continuous demographic, clinical, and PSG data between the RA and control groups were conducted through 2-tailed t tests; χ 2 analyses were used for categorical variables. Relationships between inflammatory markers and sleep variables were examined using multiple regression while controlling for the group factor, depressive symptoms, and physical health functioning, with inclusion of inflammatory markers assessed at 11:00 PM and 8:00 AM to determine whether inflammation before sleep (11:00 PM) was associated with SWS, for example, or whether SWS amounts were associated with inflammation in the morning (8:00 AM). Data entry and analyses were conducted using SPSS version 22 (IBM, 2013) . Means (standard deviation) are reported as M (SD).
RESULTS
Demographic and Clinical Characteristics
Demographic characteristics for the RA and control groups are described in Table 1 . Age, sex, ethnicity, BMI, educational level, marital status, and employment status were similar for both groups. Although there were more nonwhite participants in the RA group compared with controls, the difference was not significant (χ 2 = 3.57, p = .06). Within the RA group, M (SD) DAS28-ESR and DAS28-CRP were 3.7 (1.7) and 3.3 (1.0) respectively, indicative of moderate disease activity.
Subjective Sleep Measures, Self-Reported Pain, and Health Functioning Subjective reports of sleep showed significant differences between RA patients and controls, in which 67% of RA patients had a PSQI score exceeding 5, indicating poor sleep quality, compared to 22% in the control group (Table 2) . In addition, 33% of the RA participants met criteria for current persistent insomnia disorder, as compared with 11% of the controls (χ 2 = 4.8, p = .028). RA patients also reported more depressive symptoms, fatigue, impairments in physical health functioning, and increase in self-reported pain symptoms before and in the morning after sleep (Table 2) . However, none of the measures of sleep were correlated with self-reported pain symptoms (data not shown).
Sleep Macrostructure
Macrostructure sleep parameters for the RA and control groups are described in Table 3 . Compared with controls, the RA patients exhibited statistically significant alterations of sleep continuity measures (total sleep time, wake after sleep onset, sleep efficiency) indicative of shorter sleep duration and sleep fragmentation.
Sleep architecture measures also differed significantly between groups. In addition to lower levels of absolute amounts of stage 2 sleep, RA patients had higher levels of relative amounts of stage 3 sleep and elevated levels of REM density compared with controls. Within the RA patients, no sleep continuity or architecture measures differed by DMARD or NSAID use. However, those taking biologics had higher total sleep time (397. 
Inflammatory Activity
As expected, RA patients had higher levels of highsensitivity CRP, with a trend for higher levels of ESR, compared with controls (Table 4) .
Spontaneous (unstimulated) monocyte intracellular production of TNF at 11:00 PM was significantly higher in the RA group compared with controls (Table 4) . TLR-4-stimulated production of IL-6 at 8:00 AM was higher in RA patients compared with controls (Table 4) . Within the RA group, none of the inflammatory markers differed by the use of DMARD, biologic, or NSAID medications.
Association Between Inflammatory Activity and Sleep Macrostructure
High-sensitivity CRP or ESR, taken only in the morning after sleep, did not show any significant associations to any of the PSG sleep measures.
To explore the reciprocal relationship between cellular inflammation and objective sleep measures, we tested the associations between sleep measures and spontaneous and TLR-4-stimulated production of IL-6 and TNF taken at 11:00 PM before sleep and at 8:00 AM after a night of sleep, taking into account group, depressive symptoms, and physical functioning. Depressive symptoms and physical functioning differed between the groups and are known to influence sleep. Table 5 shows the associations between spontaneous production of IL-6 and TNF and PSG measures of sleep. For the sleep continuity measures, level of spontaneous IL-6 expression at 11:00 PM, but not TNF, was negatively associated with sleep onset latency. In contrast, sleep onset latency showed a countervailing relationship with spontaneous IL-6 expression at 8:00 AM, in which sleep onset latency was positively associated with spontaneous IL-6 expression at 8:00 AM. Together, these data suggest a reciprocal and countervailing link between sleep onset latency and constitutive IL-6 expression.
For the sleep architecture measures, level of spontaneous IL-6 expression at 11:00 PM, but not TNF, was negatively associated with stage 2 sleep and positively associated with stages 3 and 4 ( Fig. 1A) and SWS. However, none of the sleep architecture measures were associated with levels of spontaneous IL-6 or TNF expression at 8:00 AM. There was no relationship between the inflammatory markers and relative amounts of REM sleep or any of the REM measures (data not shown). Table 6 shows the associations between TLR-4-stimulated production of IL-6 and TNF and PSG measures of sleep. For the sleep continuity measures, level of stimulated TNF production, but not IL-6, at 11:00 PM was positively associated with sleep latency, negatively associated with wake after sleep onset and number of awakenings, and positively associated with sleep efficiency (Fig. 2A) , indicating that higher level of TNF production at 11:00 PM correlated with sleep maintenance. In contrast, measures of sleep maintenance (i.e., wake after sleep onset, number of awakenings, and sleep efficiency) showed countervailing associations with TNF production at 8:00 AM (Fig. 2B) .
For the sleep architecture measures, level of IL-6 production at 11:00 PM was positively associated with SWS as a trend. In contrast, stage 4 sleep showed a countervailing negative association with IL-6 production at 8:00 AM RA = rheumatoid arthritis; ESR = erythrocyte sedimentation rate; hs-CRP = high-sensitivity C-reactive protein, natural log; TNF = tumor necrosis factor; IL-6 = interleukin 6.
Results are presented as M (SD).
a For spontaneous and stimulated production of IL-6 and TNF, results are presented as % of total number of monocytes expressing TNF or IL-6, respectively, natural log transformed.
( Fig. 1B) . In addition, level of TNF production at 11:00 PM, but not IL-6, was negatively associated with stage 1 sleep. There was no relationship between the TLR-4-stimulated production of inflammatory cytokines and relative amounts of REM sleep or any of the REM measures (data not shown). There were no interactions between group and cellular markers of inflammation on sleep measures (IL6: F(1,45) = 1.92, p = .18; TNF: F(1,45) = 1.317, p = .26), indicating that the identified relationships between the inflammatory markers and sleep measures were similar in the two groups. In other words, the relationships between cellular inflammation and sleep measures were not stronger in the RA patients as compared with the controls.
DISCUSSION
Basic research on neural-immune signaling has shown that peripheral proinflammatory cytokines exert potent effects on neural processes, which lead to a constellation of behavior changes including abnormal sleep (33) . In this study, RA patients showed disturbances in sleep continuity, increases in sleep depth, and increases in systemic and cellular markers of inflammation as compared with controls. In addition, in both groups of RA patients and controls, the associations between cellular inflammation and sleep showed countervailing effects dependent on time of assessment of inflammation, cytokine, and sleep measures. For example, level of stimulated production of TNF before sleep was associated with improvements in sleep maintenance, whereas disturbance of sleep maintenance correlated with increases in the production of TNF in the morning. Although these correlational data do not test a causal pathway, it is possible that sleep fragmentation leads to increases in morning inflammation, which persists during the day (i.e., 8:00 AM and 11:00 PM levels of proinflammatory cytokines were highly correlated), and then, such inflammation has a reciprocal influence to improve sleep maintenance. The association between TNF, but not IL-6, and sleep maintenance is striking, because increases in both of these proinflammatory cytokines have separately been associated with disturbances of sleep continuity. However, the vast majority of research has not examined the relative contribution of TNF versus IL-6 on sleep; hence, these data provide novel insight into the potential unique role of TNF in regulation of sleep maintenance. A similar reciprocal loop between IL-6 and measures of sleep depth is also suggested by these correlative data. Consistent with experimental animal data, constitutive expression of IL-6 before sleep was associated with increases in stage 3, stage 4, and slow-wave sleep, with evidence that stimulated production of IL-6 before sleep was also associated with increases in slow-wave sleep. In turn, increases in stage 4 correlated with decreases in the stimulated production of IL-6 in the morning, consistent with the notion that amounts of slow-wave sleep might have countervailing effects on inflammation. Given the restorative effects of slowwave sleep to reduce sympathetic activity, this may be a mechanism to account for the association between stage 4 sleep and stimulated IL-6 production in the morning. Indeed, sympathetic activation is known to induce increases in inflammatory signaling and cellular inflammation (34) , and blockade of β-adrenergic tone abrogates stress-induced inflammation.
Previous studies in humans that have examined the association between inflammation and sleep have relied almost exclusively on circulating measures of cytokines (e.g., IL-6) with mixed results. For example, Burgos et al. (35) found a negative correlation between nocturnal IL-6 levels and slow-wave sleep in a small sample (n = 11) of insomniacs, whereas Hong et al. (36) found no association between circulating levels of IL-6 and slow-wave sleep; these are similar to the negative results reported here between CRP and sleep measures. Furthermore, experimental studies that have tested whether cytokines or cytokine antagonists modulate sleep structure have also yielded mixed results. Whereas pharmacologic increases in interferon-alpha, a proinflammatory cytokine, administered for 12 weeks, induced decreases in slow-wave sleep in patients with hepatitis C (30), pharmacologic blockade with infliximab, an anti TNF monoclonal antibody, had no effect on sleep architecture (37) . We have previously found that etanercept, a TNF antagonist, produces robust decreases of REM sleep in abstinent alcoholdependent participants but had no effect on slow-wave sleep (26) .
A number of other mechanisms are thought to contribute to sleep disturbance in RA patients. For example, pain is often cited as a factor that leads to disturbances in sleep (38, 39) . Indeed, sleep disturbance has been found to alter conditioned pain modulation (40) and to increase pain perception in RA patients (16) . In addition, a limited number of studies, with partially overlapping patient cohorts, have demonstrated significant associations between RA disease activity (i.e., pain symptoms) and sleep macrostructure parameters (11, 41, 42) , although other studies have found no associations (9, 13) . Nevertheless, this study did not find any association between self-reported pain and subjective or objective measures of sleep. Other factors that might adversely affect sleep homeostasis in RA patients include altered melatonin secretion (43) , comorbidities (4), primary sleep disorders (44) , analgesics (45) , and diseasemodifying medications (46, 47) , although use of RA-specific medications did not alter the sleep measures with the exception of increases in total sleep time in those taking biologic medications.
Fragmentation of sleep with reduced sleep efficiency was found in the RA patients, consistent with four previous PSG studies (9) (10) (11) (12) . Nevertheless, a relatively large ambulatory PSG study revealed normative sleep continuity measures in an outpatient RA sample (42) , suggesting that differences in clinical characteristics and disease activity of the RA patients or other methodological factors might have led to these mixed findings (14) .
Although our study holds several advantages compared with previous controlled PSG studies in RA patients, a few limitations deserve consideration. First, although the present work constitutes, to date, one of the largest controlled sleep laboratory studies of RA patients, the sample was relatively small. Second, although the groups were matched for important demographic factors, such as age, sex, BMI, race, ethnicity, and education level, physical activity was not considered. Third, we did not include a multiple sleep latency test to objectively evaluate abnormal daytime sleepiness. Previous multiple sleep latency test results in RA patients have been mixed (9, 10, 12) , and future studies should ideally implement this measure. Fourth, EEG power spectral analysis might have added further detail to the findings, although these analyses are beyond the scope of this report.
The neurobiological mechanisms that contribute to disordered sleep in RA and other chronic inflammatory disorders are not well-known. Indeed, the present study is the first to incorporate objective sleep assessment in conjunction with examination of cellular inflammation before and after a sleep period and to provide evidence that cellular inflammation has a reciprocal relationship with sleep maintenance and sleep depth. Depending on the time of day, countervailing associations are found between TNF production and measures of sleep maintenance and between IL-6 production and slow-wave sleep, which suggest the possibility of a homeostatic relationship between sleep maintenance, slow-wave sleep, and cellular inflammation that is cytokine specific.
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